<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
<ui>1471-2431-12-193</ui>
<ji>1471-2431</ji>
<fm>
<dochead>Research article</dochead>
<bibl>
<title>
<p>Lymphocyte respiration in children with Trisomy 21</p></title>
<aug>
<au id="A1" ca="yes"><snm>Aburawi</snm><mi>H</mi><fnm>Elhadi</fnm><insr iid="I1"/><email>e.aburawi@uaeu.ac.ae</email></au>
<au id="A2"><snm>Souid</snm><fnm>Abdul-Kader</fnm><insr iid="I1"/><email>asouid@uaeu.ac.ae</email></au></aug>
<insg>
<ins id="I1"><p>Department of Pediatrics, UAE University, P.O. Box 17666, Al Ain, United Arab Emirates</p></ins></insg>
<source>BMC Pediatrics</source>
<section><title><p>Genetics and congenital disorders</p></title></section><issn>1471-2431</issn>
<pubdate>2012</pubdate>
<volume>12</volume>
<issue>1</issue>
<fpage>193</fpage>
<url>http://www.biomedcentral.com/1471-2431/12/193</url><xrefbib><pubidlist><pubid idtype="doi">10.1186/1471-2431-12-193</pubid><pubid idtype="pmpid">23249287</pubid></pubidlist></xrefbib></bibl>
<history><rec><date><day>10</day><month>5</month><year>2012</year></date></rec><acc><date><day>12</day><month>12</month><year>2012</year></date></acc><pub><date><day>18</day><month>12</month><year>2012</year></date></pub></history>
<cpyrt><year>2012</year><collab>Aburawi and Souid; licensee BioMed Central Ltd.</collab><note>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</note></cpyrt>
<kwdg>
<kwd>Oxygen</kwd>
<kwd>Respiration</kwd>
<kwd>Mitochondria</kwd>
<kwd>Trisomy 21</kwd>
<kwd>Hypothyroidism</kwd></kwdg>
<abs>
<sec>
<st>
<p>Abstract</p></st>
<sec>
<st>
<p>Background</p></st>
<p>This study measured lymphocyte mitochondrial O<sub>2</sub> consumption (cellular respiration) in children with trisomy 21.</p></sec>
<sec>
<st>
<p>Methods</p></st>
<p>Peripheral blood mononuclear cells were isolated from whole blood of trisomy 21 and control children and these cells were immediately used to measure cellular respiration rate. [O<sub>2</sub>] was determined as a function of time from the phosphorescence decay rates (1/&#964;) of Pd (II)-<it>meso</it>-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin. In sealed vials containing lymphocytes and glucose as a respiratory substrate, [O<sub>2</sub>] declined linearly with time, confirming the zero-order kinetics of O<sub>2</sub> conversion to H<sub>2</sub>O by cytochrome oxidase. The rate of respiration (<it>k</it>, in &#956;M O<sub>2</sub> min<sup>-1</sup>), thus, was the negative of the slope of [O<sub>2</sub>] <it>vs.</it> time. Cyanide inhibited O<sub>2</sub> consumption, confirming that oxidation occurred in the mitochondrial respiratory chain.</p></sec>
<sec>
<st>
<p>Results</p></st>
<p>For control children (age = 8.8 &#177; 5.6 years, n = 26), the mean (&#177; SD) value of <it>k</it><sub><it>c</it></sub> (in &#956;M O<sub>2</sub> per min per 10<sup>7</sup> cells) was 1.36 &#177; 0.79 (coefficient of variation, Cv = 58%; median = 1.17; range = 0.60 to 3.12; -2SD = 0.61). For children with trisomy 21 (age = 7.2 &#177; 4.6 years, n = 26), the values of <it>k</it><sub><it>c</it></sub> were 0.82 &#177; 0.62 (Cv = 76%; median = 0.60; range = 0.20 to 2.80), <it>p</it>&lt;0.001. Similar results (<it>p</it>&lt;0.000) were obtained after excluding the five trisomy 21 children with elevated serum TSH (values &gt;6.1 mU/L). Fourteen of 26 (54%) children with trisomy 21 had <it>k</it><sub><it>c</it></sub> values of 0.20 to 0.60 (i.e., &lt;&#8722;2SD). The values of <it>k</it><sub><it>c</it></sub> positively correlated with body-mass index (BMI, <it>R</it> &gt;0.302), serum creatinine  (<it>R</it> &gt;0.507), blood urea nitrogen (BUN, <it>R</it> &gt;0.535) and albumin (<it>R</it> &gt;0.446).</p></sec>
<sec>
<st>
<p>Conclusions</p></st>
<p>Children with trisomy 21 in this study have reduced lymphocyte bioenergetics. The clinical importance of this finding requires further studies.</p></sec></sec></abs></fm>
<bdy>
<sec>
<st>
<p>Background</p></st>
<p>Trisomy 21 is the most common chromosomal anomaly worldwide, affecting about 1 in 700 newborns 
<abbrgrp>
<abbr bid="B1">1</abbr></abbrgrp>. These individuals typically have low resting metabolic rates 
<abbrgrp>
<abbr bid="B2">2</abbr></abbrgrp> and are particularly susceptible to infections 
<abbrgrp>
<abbr bid="B3">3</abbr></abbrgrp> and hypothyroidism 
<abbrgrp>
<abbr bid="B4">4</abbr></abbrgrp>. Moreover, defects in the inner mitochondrial membrane potential 
<abbrgrp>
<abbr bid="B5">5</abbr></abbrgrp> and mitochondrial respiratory chain enzymes are documented in these patients 
<abbrgrp>
<abbr bid="B6">6</abbr>
<abbr bid="B7">7</abbr></abbrgrp>. Mitochondrial disturbances, increased oxidative stress and apoptosis have been described in the neurons, predisposing to precocious Alzheimer&#8217;s disease 
<abbrgrp>
<abbr bid="B8">8</abbr></abbrgrp>. Alterations in metabolic enzymes (e.g., monoamine oxidase-B, cytochrome oxidase, isocitrate dehydrogenase and glutamate dehydrogenase) have been also linked to impaired energy metabolism in trisomy 21 children 
<abbrgrp>
<abbr bid="B9">9</abbr></abbrgrp>. Calcium levels are lower than in control children, which may alter cellular signaling 
<abbrgrp>
<abbr bid="B10">10</abbr></abbrgrp>.</p>
<p>Increased congenital heart disease and other major anomalies are exceptionally frequent in children with trisomy 21. It is not known whether these defects are linked to the biological impairments described above.</p>
<p>The use of the phosphorescence oxygen analyzer to measure lymphocyte respiration was recently reported. Lymphocytes were shown to be suitable for screening of certain mitochondrial disorders 
<abbrgrp>
<abbr bid="B11">11</abbr></abbrgrp>. These methodologies were used to measure lymphocyte respiration rates in children with trisomy 21 and compare them with rates in children without this disorder.</p></sec>
<sec>
<st>
<p>Methods</p></st>
<sec>
<st>
<p>Reagents and solutions</p></st>
<p>Pd (II) complex of <it>meso</it>-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin was purchased from Porphyrin Products (Logan, UT). Glucose oxidase (powder from <it>Aspergillus niger),</it> D (+) glucose anhydrous, Histopaque-1077 and remaining reagents were purchased from Sigma-Aldrich (St. Louis, MO).</p>
<p>Pd phosphor solution (2.5 mg/ml = 2 mM) was prepared in distilled water (dH<sub>2</sub>O) and stored at &#8722;20&#176;C. Glucose oxidase solution was prepared in dH<sub>2</sub>O (10 mg/mL) and stored at &#8722;20&#176;C. Sodium cyanide (NaCN) solution (1.0 M) was prepared in dH<sub>2</sub>O; the <it>p</it>H was adjusted to ~7.0 with 12N HCl and stored at &#8722;20&#176;C. Phosphate-buffered saline (PBS) containing glucose (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.4 mM KH<sub>2</sub>PO<sub>4</sub> and 10 mM glucose; <it>p</it>H 7.4) was stored at 4&#176;C.</p></sec>
<sec>
<st>
<p>Subjects</p></st>
<p>Venous blood samples (5 to 8 mL) were collected in heparin tubes and processed in &lt;2 hr for peripheral blood mononuclear cell (PBMC) isolation and O<sub>2</sub> measurement. Blood was also collected from age- and gender-matched healthy controls. All trisomy 21 participants attended the outpatient facilities at Tawam and Al Ain Hospitals (Al Ain city, Abu Dhabi) for routine visits. All control participants were healthy children who had no medical complaints.</p>
<p>The study was approved by the institutional review board for protection of human subjects. Informed consent was obtained for each participating subject.</p></sec>
<sec>
<st>
<p>PBMC isolation</p></st>
<p>Plasma was collected from blood samples by centrifugation and possessed for Comprehensive Metabolic Panel and lipid profile. The samples were then diluted with equal volume of phosphate-buffered saline (PBS) containing 10 mM glucose and gently layered on the top of 10 mL Histopaque-1077. The mixtures were centrifuged at 15&#176;C, 400 x<it>g</it> for 30 min. Collected PBMC were diluted with the same solution and re-centrifuged as above. The pellets were suspended in PBS, 10 mM glucose, 3 &#956;M Pd phosphor and 0.5% fat-free bovine serum albumin for O<sub>2</sub> measurements at 37&#176;C. Cell count and viability were determined by light microscopy, using a hemocytometer under standard trypan blue staining conditions. Only trypan blue-negative cells (&gt;95%) were counted.</p></sec>
<sec>
<st>
<p>Oxygen instrument</p></st>
<p>A phosphorescence oxygen analyzer that measures dissolved O<sub>2</sub> in solutions as function of time was used to determine the rate of PBMC respiration 
<abbrgrp>
<abbr bid="B12">12</abbr>
<abbr bid="B13">13</abbr></abbrgrp>. This method is based on the principle that O<sub>2</sub> quenches the phosphorescence of a palladium phosphor 
<abbrgrp>
<abbr bid="B14">14</abbr></abbrgrp>.</p>
<p>The Pd (II) derivative of <it>meso</it>-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin had an absorption maximum at 625 nm and a phosphorescence emission maximum at 800 nm. Samples were exposed to light flashes (10 per sec) from a pulsed light-emitting diode array with a peak output at 625 nm. Emitted phosphorescent light was detected by a Hamamatsu photomultiplier tube after first passing it through a wide-band interference filter centered at 800 nm. Amplified phosphorescence was digitized at 1&#8211;2 MHz using an analog/digital converter (PCI-DAS 4020/12 I/O Board) with 1 to 20 MHz outputs.</p>
<p>The phosphorescence decay rate (1/&#964;) was characterized by a single exponential; I = Ae<sup>-<it>t</it>/&#964;</sup>, where I = Pd phosphor phosphorescence intensity. The values of 1/&#964; were linear with dissolved O<sub>2</sub>: 1/&#964; = 1/&#964;<sup>o</sup> + <it>k</it><sub><it>q</it></sub>[O<sub>2</sub>, where 1/&#964; = the phosphorescence decay rate in the presence of O<sub>2</sub>, 1/&#964;<sup>o</sup> = the phosphorescence decay rate in the absence of O<sub>2</sub>, and <it>k</it><sub>q</sub> = the second-order O<sub>2</sub> quenching rate constant in sec<sup>-1</sup> &#956;M<sup>-1</sup> (14). For calibration, the reaction contained PBS, 3 &#956;M Pd phosphor, 0.5% fat-free albumin, 50 &#956;g/mL glucose oxidase and various concentrations of &#946;-glucose 
<abbrgrp>
<abbr bid="B11">11</abbr></abbrgrp>.</p>
<p>Cellular respiration was measured at 37&#176;C in 1.0-mL sealed vials. Mixing was carried out with the aid of parylene-coated stirring bars. The respiratory substrates were endogenous metabolic fuels supplemented with glucose.</p></sec>
<sec>
<st>
<p>Statistical analysis</p></st>
<p>The data are summarized by arithmetic mean and standard deviation. Mann&#8211;Whitney <it>U</it> test was used for nonparametric values. <it>P</it>&lt;0.05 was considered significant.</p></sec></sec>
<sec>
<st>
<p>Results</p></st>
<p>In cell suspensions sealed from air, [O<sub>2</sub>] decreased linearly with time, indicating the kinetics of mitochondrial O<sub>2</sub> consumption was zero-order. The rate of respiration (<it>k</it>, in &#956;M O<sub>2</sub>/min) was thus the negative of the slope d[O<sub>2</sub>]/d<it>t</it>. Cyanide markedly inhibited respiration (&#8805;96%), confirming O<sub>2</sub> was consumed mainly by the mitochondrial respiratory chain.</p>
<p>Lymphocyte respiration was measured in 26 children with trisomy 21 and 26 control children. Representative O<sub>2</sub> runs are shown in Figure&#8201;
<figr fid="F1">1a</figr>-b. For trisomy 21 children, the rate of respiration (<it>k</it><sub><it>c</it></sub>, in &#956;M O<sub>2</sub> per min per 10<sup>7</sup> cells, mean &#177; SD, n = 26) was 0.82 &#177; 0.62 (median = 0.60; range = 0.20 to 2.80), Table&#8201;
<tblr tid="T1">1</tblr>. The values of <it>k</it><sub><it>c</it></sub> for control children (n = 26) were 1.36 &#177; 0.79 (median = 1.17; range = 0.60 to 3.12; -2SD = 0.61). The <it>p</it> value for <it>k</it><sub><it>c</it></sub> between trisomy 21 and control children was &lt;0.001, Figure&#8201;
<figr fid="F2">2</figr>. Similar results with higher significance (<it>p</it>&lt;0.000) were obtained after excluding the five children with trisomy 21 and elevated serum TSH (values &gt;6.1 mU/L). Fourteen of 26 (54%) children with trisomy 21 had <it>k</it><sub><it>c</it></sub> values of 0.20 to 0.60 (&lt;&#8722;2SD).</p>
<fig id="F1"><title><p>Figure 1</p></title><caption><p>Representative O<sub>2</sub> runs for lymphocyte respiration in a 15-year-old male with trisomy 21 (Panel A, Subject 8 in Table&#8201;
<tblr tid="T1">1</tblr>) and control subject (Panel B)</p></caption><text>
   <p><b>Representative O</b><sub><b>2</b></sub><b>runs for lymphocyte respiration in a 15-year-old male with trisomy 21 (Panel a, Subject 8 in  Table</b><tblr tid="T1">1</tblr><b>) and control subject (Panel b).</b> The lines are best linear fits (<it>R</it><sup>2</sup> >0.830). The additions of 10 mM NaCN and 50 &#956;g/mL glucose oxidase are shown.</p>
</text><graphic file="1471-2431-12-193-1"/></fig><table id="T1">
<title>
<p>Table 1</p></title>
<caption>
<p><b>Rates of lymphocyte respiration, thyroid function and clinical findings in trisomy 21 children</b></p></caption>
<tgroup align="left" cols="8">
<colspec align="left" colname="c1" colnum="1" colwidth="1*"/>
<colspec align="left" colname="c2" colnum="2" colwidth="1*"/>
<colspec align="left" colname="c3" colnum="3" colwidth="1*"/>
<colspec align="left" colname="c4" colnum="4" colwidth="1*"/>
<colspec align="left" colname="c5" colnum="5" colwidth="1*"/>
<colspec align="left" colname="c6" colnum="6" colwidth="1*"/>
<colspec align="left" colname="c7" colnum="7" colwidth="1*"/>
<colspec align="left" colname="c8" colnum="8" colwidth="1*"/>
<thead valign="top">
<row rowsep="1">
<entry colname="c1">
<p><b>Children No.</b></p></entry>
<entry colname="c2">
<p><b>Age (yr)</b></p></entry>
<entry colname="c3">
<p><b>Gender</b></p></entry>
<entry colname="c4">
<p><b>BMI  (kg/m</b><sup><b>2</b></sup><b>)</b></p></entry>
<entry colname="c5">
<p><b><it>k</it></b><sub><b><it>c</it></b></sub> <b>(&#956;M O</b><sub><b>2</b></sub> <b>min</b><sup><b>-1</b></sup> <b>per 10</b><sup><b>7</b></sup> <b>cells)</b></p></entry>
<entry colname="c6">
<p><b>TSH  (mIU/L)</b></p></entry>
<entry colname="c7">
<p><b>Free T4  (pmol/L)</b></p></entry>
<entry colname="c8">
<p><b>Clinical status</b></p></entry></row></thead><tfoot>
<p>AVSD, atrioventricular septal defect; VSD, ventricular septal defect; ASD, atrial septal defect; PDA, patent ductus arteriosus; CV, coefficient of variation. NA, not available.</p>
<p>In normal 2 to7 year-old children, the TSH values are 0.10 to 5.9 mU/L (mean = 2.2 mU/L); in normal 9 to 16 year-old children, the TSH values are 0.20 to 6.1 mU/L (mean = 2.3 mU/L).</p>
<p>Reference ranges for free T4 are 11.0 to 22.6 pmol/L in children 1 to 5 years of age, 11.6 to 21.5 pmol/L in children 6 to 10 years of age, and 12.0 to 20.6 pmol/L in children 11 to 19 years of age (
<url>https://www.labcorp.com/wps/portal/provider</url>).</p>
<p>* On thyroxin prior to O<sub>2</sub> consumption testing.</p></tfoot><tbody valign="top">
<row>
<entry colname="c1">
<p>1</p></entry>
<entry colname="c2">
<p>1.5</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>12.8</p></entry>
<entry colname="c5">
<p>1.6</p></entry>
<entry colname="c6">
<p>3.5</p></entry>
<entry colname="c7">
<p>20.7</p></entry>
<entry colname="c8">
<p>AVSD</p></entry></row>
<row>
<entry colname="c1">
<p>2</p></entry>
<entry colname="c2">
<p>5</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>16.1</p></entry>
<entry colname="c5">
<p>2.0</p></entry>
<entry colname="c6">
<p>1.6</p></entry>
<entry colname="c7">
<p>14.7</p></entry>
<entry colname="c8">
<p>celiac disease</p></entry></row>
<row>
<entry colname="c1">
<p>3</p></entry>
<entry colname="c2">
<p>17</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>28.6</p></entry>
<entry colname="c5">
<p>1.2</p></entry>
<entry colname="c6">
<p>4.9</p></entry>
<entry colname="c7">
<p>9.5</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>4</p></entry>
<entry colname="c2">
<p>12</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>16.3</p></entry>
<entry colname="c5">
<p>0.6</p></entry>
<entry colname="c6">
<p>2.6</p></entry>
<entry colname="c7">
<p>10</p></entry>
<entry colname="c8">
<p>AVSD</p></entry></row>
<row>
<entry colname="c1">
<p>5</p></entry>
<entry colname="c2">
<p>12</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>30.8</p></entry>
<entry colname="c5">
<p>1.2</p></entry>
<entry colname="c6">
<p>3.8</p></entry>
<entry colname="c7">
<p>13.2</p></entry>
<entry colname="c8">
<p>VSD</p></entry></row>
<row>
<entry colname="c1">
<p>6</p></entry>
<entry colname="c2">
<p>9</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>17.1</p></entry>
<entry colname="c5">
<p>0.6</p></entry>
<entry colname="c6">
<p>2.6</p></entry>
<entry colname="c7">
<p>NA</p></entry>
<entry colname="c8">
<p>bronchial asthma</p></entry></row>
<row>
<entry colname="c1">
<p>7<sup>*</sup></p></entry>
<entry colname="c2">
<p>15</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>30.2</p></entry>
<entry colname="c5">
<p>0.6</p></entry>
<entry colname="c6">
<p>2.8</p></entry>
<entry colname="c7">
<p>10.0</p></entry>
<entry colname="c8">
<p>aortic stenosis, hypothyroidism</p></entry></row>
<row>
<entry colname="c1">
<p>8</p></entry>
<entry colname="c2">
<p>15</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>44.3</p></entry>
<entry colname="c5">
<p>2.8</p></entry>
<entry colname="c6">
<p>13.2</p></entry>
<entry colname="c7">
<p>11.0</p></entry>
<entry colname="c8">
<p>Moya Moya disease, hypothyroidism</p></entry></row>
<row>
<entry colname="c1">
<p>9</p></entry>
<entry colname="c2">
<p>3</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>13.8</p></entry>
<entry colname="c5">
<p>0.4</p></entry>
<entry colname="c6">
<p>3.7</p></entry>
<entry colname="c7">
<p>14.2</p></entry>
<entry colname="c8">
<p>bronchial asthma</p></entry></row>
<row>
<entry colname="c1">
<p>10</p></entry>
<entry colname="c2">
<p>2</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>15.2</p></entry>
<entry colname="c5">
<p>0.6</p></entry>
<entry colname="c6">
<p>5.3</p></entry>
<entry colname="c7">
<p>13.0</p></entry>
<entry colname="c8">
<p>obstructive sleep apnea, low vitamin D</p></entry></row>
<row>
<entry colname="c1">
<p>11</p></entry>
<entry colname="c2">
<p>3</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>14.5</p></entry>
<entry colname="c5">
<p>0.5</p></entry>
<entry colname="c6">
<p>2.9</p></entry>
<entry colname="c7">
<p>15.8</p></entry>
<entry colname="c8">
<p>ASD, PDA</p></entry></row>
<row>
<entry colname="c1">
<p>12</p></entry>
<entry colname="c2">
<p>5</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>17.5</p></entry>
<entry colname="c5">
<p>0.9</p></entry>
<entry colname="c6">
<p>2.6</p></entry>
<entry colname="c7">
<p>9.9</p></entry>
<entry colname="c8">
<p>VSD</p></entry></row>
<row>
<entry colname="c1">
<p>13<sup>*</sup></p></entry>
<entry colname="c2">
<p>4</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>15.7</p></entry>
<entry colname="c5">
<p>0.2</p></entry>
<entry colname="c6">
<p>12.6</p></entry>
<entry colname="c7">
<p>11.6</p></entry>
<entry colname="c8">
<p>hypothyroidism</p></entry></row>
<row>
<entry colname="c1">
<p>14</p></entry>
<entry colname="c2">
<p>10</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>NA</p></entry>
<entry colname="c5">
<p>0.8</p></entry>
<entry colname="c6">
<p>5.1</p></entry>
<entry colname="c7">
<p>10.4</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>15</p></entry>
<entry colname="c2">
<p>6</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>18.7</p></entry>
<entry colname="c5">
<p>0.4</p></entry>
<entry colname="c6">
<p>5.1</p></entry>
<entry colname="c7">
<p>10.5</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>16</p></entry>
<entry colname="c2">
<p>4</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>14.8</p></entry>
<entry colname="c5">
<p>1.2</p></entry>
<entry colname="c6">
<p>3.6</p></entry>
<entry colname="c7">
<p>11.9</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>17</p></entry>
<entry colname="c2">
<p>9</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>16</p></entry>
<entry colname="c5">
<p>0.7</p></entry>
<entry colname="c6">
<p>3.9</p></entry>
<entry colname="c7">
<p>10.7</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>18</p></entry>
<entry colname="c2">
<p>1.5</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>16.3</p></entry>
<entry colname="c5">
<p>1.5</p></entry>
<entry colname="c6">
<p>11.6</p></entry>
<entry colname="c7">
<p>11.9</p></entry>
<entry colname="c8">
<p>hypothyroidism</p></entry></row>
<row>
<entry colname="c1">
<p>19</p></entry>
<entry colname="c2">
<p>5</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>NA</p></entry>
<entry colname="c5">
<p>1.0</p></entry>
<entry colname="c6">
<p>2.9</p></entry>
<entry colname="c7">
<p>11.1</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>20</p></entry>
<entry colname="c2">
<p>6</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>20.7</p></entry>
<entry colname="c5">
<p>0.3</p></entry>
<entry colname="c6">
<p>3.9</p></entry>
<entry colname="c7">
<p>10.4</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>21</p></entry>
<entry colname="c2">
<p>8</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>31.4</p></entry>
<entry colname="c5">
<p>0.4</p></entry>
<entry colname="c6">
<p>5.1</p></entry>
<entry colname="c7">
<p>10.5</p></entry>
<entry colname="c8">
<p>asthma, myelomeningocele</p></entry></row>
<row>
<entry colname="c1">
<p>22</p></entry>
<entry colname="c2">
<p>2</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>14.3</p></entry>
<entry colname="c5">
<p>0.3</p></entry>
<entry colname="c6">
<p>7.7</p></entry>
<entry colname="c7">
<p>11.2</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>23</p></entry>
<entry colname="c2">
<p>7</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>17.8</p></entry>
<entry colname="c5">
<p>0.3</p></entry>
<entry colname="c6">
<p>1.3</p></entry>
<entry colname="c7">
<p>9.3</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row>
<entry colname="c1">
<p>24</p></entry>
<entry colname="c2">
<p>8</p></entry>
<entry colname="c3">
<p>F</p></entry>
<entry colname="c4">
<p>23.2</p></entry>
<entry colname="c5">
<p>0.2</p></entry>
<entry colname="c6">
<p>3.7</p></entry>
<entry colname="c7">
<p>11.3</p></entry>
<entry colname="c8">
<p>AVSD</p></entry></row>
<row>
<entry colname="c1">
<p>25</p></entry>
<entry colname="c2">
<p>6</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>35.1</p></entry>
<entry colname="c5">
<p>0.2</p></entry>
<entry colname="c6">
<p>3.6</p></entry>
<entry colname="c7">
<p>14.1</p></entry>
<entry colname="c8">
<p>AVSD</p></entry></row>
<row>
<entry colname="c1">
<p>26</p></entry>
<entry colname="c2">
<p>4</p></entry>
<entry colname="c3">
<p>M</p></entry>
<entry colname="c4">
<p>13.6</p></entry>
<entry colname="c5">
<p>0.7</p></entry>
<entry colname="c6">
<p>6.4</p></entry>
<entry colname="c7">
<p>14.1</p></entry>
<entry colname="c8">
<p>normal</p></entry></row>
<row rowsep="1">
<entry colname="c1">
<p>mean &#177; SD (CV)</p></entry>
<entry colname="c2">
<p>6.9 &#177; 4.4</p></entry>
<entry colname="c3"/>
<entry colname="c4">
<p>20.6 &#177; 8.3 (40%)</p></entry>
<entry colname="c5">
<p>0.82 &#177; 0.62 (76%)</p></entry>
<entry colname="c6">
<p>4.8 &#177; 3.1</p></entry>
<entry colname="c7">
<p>12.0 &#177; 2.5</p></entry>
<entry colname="c8"/></row></tbody></tgroup></table>
<fig id="F2"><title><p>Figure 2</p></title><caption><p>Lymphocyte respiration in 26 children with trisomy 21 and 26 control children</p></caption><text>
   <p><b>Lymphocyte respiration in 26 children with trisomy 21 and 26 control children.</b> The horizontal lines are mean values.</p>
</text><graphic file="1471-2431-12-193-2"/></fig>
<p>In children with trisomy 21 and normal TSH (n = 21), the <it>k</it><sub><it>c</it></sub> value did not correlate with the TSH level (<it>R</it><sup><it>2</it></sup> &gt;0.072, Figure&#8201;
<figr fid="F3">3a</figr>). By contrast, in children with trisomy 21 and abnormal lymphocyte respiration (<it>k</it><sub><it>c</it></sub> &lt; 0.61, n = 14), the <it>k</it><sub><it>c</it></sub> value correlated with the TSH level (<it>R</it><sup><it>2</it></sup> &gt;0.225, <it>R</it> &gt;0.474, Figure&#8201;
<figr fid="F3">3b</figr>).</p>
<fig id="F3"><title><p>Figure 3</p></title><caption><p>Lymphocyte respiration in children with trisomy 21 as a function of serum TSH</p></caption><text>
   <p><b>Lymphocyte respiration in children with trisomy 21 as a function of serum TSH. </b><b><it>Panel a:</it></b> Circles, children (n = 21) with trisomy 21 and normal TSH (levels &#8804;5.3 mU/L; line is the best linear fit, <it>R</it><sup>2</sup> > 0.0727); diamonds, children (n = 5) with trisomy 21 and elevated TSH (levels 7.7 to 13.2 mU/L). <b><it>Panel b:</it></b> Children (n = 14) with trisomy 21 and abnormal (low) rate of respiration (<it>k</it><sub><it>c</it></sub> &lt; 0.60 &#956;M O<sub>2</sub> per min per 10<sup>7</sup> cells). The horizontal line reflects upper limit of normal TSH (&lt;6.1 mU/L, please see footnote to Table&#8201;
<tblr tid="T1">1</tblr>).</p>
</text><graphic file="1471-2431-12-193-3"/></fig>
<p>Five children with trisomy 21 had elevated TSH levels (&gt;6.1 mIU/L). Their median TSH was 12.6 mIU/L (range, 6.4 to 13.2) and median <it>k</it><sub><it>c</it></sub> was 0.7 &#956;M O<sub>2</sub> per min per 10<sup>7</sup> cells (range, 0.2 to 2.8). Subject 8 (15-year-old adolescent male) had a TSH level of 13.2 mIU/L and a <it>k</it><sub><it>c</it></sub> values of 2.8 &#956;M O<sub>2</sub> per min per 10<sup>7</sup> cells (Table&#8201;
<tblr tid="T1">1</tblr> and Figure&#8201;
<figr fid="F1">1a</figr>).</p>
<p>There were 8 children with trisomy 21 and congenital heart disease. Their median <it>k</it><sub><it>c</it></sub> value was 0.6 &#956;M O<sub>2</sub> per min per 10<sup>7</sup> cells (range, 0.2 to 1.6), and did not significantly differ from the remaining children (<it>p</it> = 0.238).</p>
<p>In children with trisomy 21, the <it>k</it><sub><it>c</it></sub> positively correlated with BMI (<it>R</it> &gt;0.302, Figure&#8201;
<figr fid="F4">4a</figr>), serum creatinine (<it>R</it> &gt;0.507), BUN (<it>R</it> &gt;0.535) and albumin (<it>R</it> &gt;0.446, Figure&#8201;
<figr fid="F4">4b</figr>), Table&#8201;
<tblr tid="T2">2</tblr>.</p>
<fig id="F4"><title><p>Figure 4</p></title><caption><p>BMI (Panel A) and serum albumin (Panel B) as a function of rates of lymphocyte respiration (<it>k</it><sub><it>c</it></sub>) in trisomy 21 children</p></caption><text>
   <p>
      <b>BMI (Panel a) and serum albumin (Panel b) as a function of rates of lymphocyte respiration (</b>
      <b>
         <it>k</it>
      </b>
      <sub>
         <b>
            <it>c</it>
         </b>
      </sub>
      <b>) in trisomy 21 children.</b>
   </p>
</text><graphic file="1471-2431-12-193-4"/></fig><table id="T2">
<title>
<p>Table 2</p></title>
<caption>
<p><b>Correlations (</b><b><it>R</it></b><b>) between serum metabolic parameters and rates of lymphocyte respiration in trisomy 21  (n = 23) and control (n = 25) children</b><sup><b>*</b></sup></p></caption>
<tgroup align="left" cols="12">
<colspec align="left" colname="c1" colnum="1" colwidth="1*"/>
<colspec align="left" colname="c2" colnum="2" colwidth="1*"/>
<colspec align="left" colname="c3" colnum="3" colwidth="1*"/>
<colspec align="left" colname="c4" colnum="4" colwidth="1*"/>
<colspec align="left" colname="c5" colnum="5" colwidth="1*"/>
<colspec align="left" colname="c6" colnum="6" colwidth="1*"/>
<colspec align="left" colname="c7" colnum="7" colwidth="1*"/>
<colspec align="left" colname="c8" colnum="8" colwidth="1*"/>
<colspec align="left" colname="c9" colnum="9" colwidth="1*"/>
<colspec align="left" colname="c10" colnum="10" colwidth="1*"/>
<colspec align="left" colname="c11" colnum="11" colwidth="1*"/>
<colspec align="left" colname="c12" colnum="12" colwidth="1*"/>
<thead valign="top">
<row rowsep="1">
<entry colname="c12" nameend="c12" namest="c1">
<p><b>Rate of respiration (</b><b><it>kc</it></b><b>)</b></p></entry></row>
<row rowsep="1">
<entry colname="c1"/>
<entry colname="c2">
<p><b>Creatinine</b></p></entry>
<entry colname="c3">
<p><b>BUN</b></p></entry>
<entry colname="c4">
<p><b>Total protein</b></p></entry>
<entry colname="c5">
<p><b>Albumin</b></p></entry>
<entry colname="c6">
<p><b>Ca</b><sup><b>2+</b></sup></p></entry>
<entry colname="c7">
<p><b>Glucose</b></p></entry>
<entry colname="c8">
<p><b>Osmolality</b></p></entry>
<entry colname="c9">
<p><b>Cholesterol</b></p></entry>
<entry colname="c10">
<p><b>HDL</b></p></entry>
<entry colname="c11">
<p><b>LDL</b></p></entry>
<entry colname="c12">
<p><b>TG</b></p></entry></row></thead><tfoot>
<p>* Serum was not available in 3 patients and 1 control.</p></tfoot><tbody valign="top">
<row>
<entry colname="c1">
<p>Trisomy 21</p></entry>
<entry colname="c2">
<p>0.507</p></entry>
<entry colname="c3">
<p>0.535</p></entry>
<entry colname="c4">
<p>0.446</p></entry>
<entry colname="c5">
<p>0.508</p></entry>
<entry colname="c6">
<p>0.137</p></entry>
<entry colname="c7">
<p>0.048</p></entry>
<entry colname="c8">
<p>0.007</p></entry>
<entry colname="c9">
<p>0.091</p></entry>
<entry colname="c10">
<p>0.145</p></entry>
<entry colname="c11">
<p>0.092</p></entry>
<entry colname="c12">
<p>0.170</p></entry></row>
<row rowsep="1">
<entry colname="c1">
<p>Control</p></entry>
<entry colname="c2">
<p>0.192</p></entry>
<entry colname="c3">
<p>0.037</p></entry>
<entry colname="c4">
<p>&#8722;0.146</p></entry>
<entry colname="c5">
<p>&#8722;0.091</p></entry>
<entry colname="c6">
<p>&#8722;0.136</p></entry>
<entry colname="c7">
<p>0.112</p></entry>
<entry colname="c8">
<p>&#8722;0.009</p></entry>
<entry colname="c9">
<p>&#8722;0.060</p></entry>
<entry colname="c10">
<p>&#8722;0.080</p></entry>
<entry colname="c11">
<p>&#8722;0.024</p></entry>
<entry colname="c12">
<p>&#8722;0.057</p></entry></row></tbody></tgroup></table></sec>
<sec>
<st>
<p>Discussion</p></st>
<p>The rates of lymphocyte respiration in the children with trisomy 21 were slower than in the control group (Figure&#8201;
<figr fid="F2">2</figr>). These differences could reflect a relatively lower rate of mitochondrial energy conversion in trisomy 21 children that may be linked to some pathological findings pertinent to this disorder, such as defects in the inner mitochondrial membrane 
<abbrgrp>
<abbr bid="B5">5</abbr>
<abbr bid="B8">8</abbr></abbrgrp>.</p>
<p>The mechanism for slower rates of lymphocyte respiration in children with trisomy 21 could be multi-factorial. For example, the thyroid hormone is a well known regulator of the rate of metabolism; and hypothyroidism is common in children with trisomy 21. As shown in Figure&#8201;
<figr fid="F3">3b</figr>, high TSH (low or ineffective thyroxin) may contribute to the slower lymphocyte respiration in some children. Thus, thyroxin replacement is expected to improve lymphocyte respiration in those with hypothyroidism.</p>
<p>Of note, normal TSH values for children 2 to 7 years of age are 0.10 to 5.9 mU/L (mean = 2.2 mU/L) and for children 9 to 16 years of age are 0.20 to 6.1 mU/L (mean = 2.3 mU/L). Using these cutoffs, lymphocyte respiration was found to be higher in euthyroid trisomy 21 children than those with hypothyroidism.</p>
<p>Body-mass index, protein metabolism (BUN, total protein and albumin), and serum creatinine positively correlated with rates of lymphocyte respiration, but only in trisomy 21 children (Table&#8201;
<tblr tid="T2">2</tblr> and Figure&#8201;
<figr fid="F4">4a</figr>-b). As previously reported, protein metabolism (proteolysis, oxidation and synthesis) is linked to obesity 
<abbrgrp>
<abbr bid="B15">15</abbr>
<abbr bid="B16">16</abbr></abbrgrp>, a finding that is common in children with trisomy 21.</p>
<p>Close correlations were documented between cerebral O<sub>2</sub> consumptions and mental function, including depression and dementia 
<abbrgrp>
<abbr bid="B17">17</abbr>
<abbr bid="B18">18</abbr></abbrgrp>. It is unknown if our finding of slower lymphocyte respiration in trisomy 21 children is applicable to other organs. Nevertheless, our findings are consistent with the recent reports on mitochondrial disturbances in those with trisomy 21 
<abbrgrp>
<abbr bid="B19">19</abbr>
<abbr bid="B20">20</abbr>
<abbr bid="B21">21</abbr>
<abbr bid="B22">22</abbr>
<abbr bid="B23">23</abbr></abbrgrp>. Decreased basal 3'-5'-cyclic adenosine monophosphate, increased reactive oxygen species and impaired NADH:ubiquinone reductase (complex I of the respiratory chain) were noted in fibroblasts from those with trisomy 21 
<abbrgrp>
<abbr bid="B20">20</abbr></abbrgrp>.</p>
<sec>
<st>
<p>Limitations of the study</p></st>
<p>No study was found in the literature that addressed lymphocyte respiration in children with trisomy 21. Additional studies are needed in a larger population.</p></sec></sec>
<sec>
<st>
<p>Conclusions</p></st>
<p>Children with trisomy 21 in this study have lower lymphocyte bioenergetics, a finding that is consistent with the known mitochondrial disturbances in these children. The clinical significance implication of this finding requires further studies.</p></sec>
<sec>
<st>
<p>Competing interests</p></st>
<p>The authors declare that they have no competing interests.</p></sec>
<sec>
<st>
<p>Authors&#8217; contributions</p></st>
<p>EHA and AKS designed the study, carried out the analysis, interpreted the data and wrote the manuscript. Both authors read and approved the final manuscript.</p></sec></bdy>
<bm>
<ack>
<sec>
<st>
<p>Acknowledgements</p></st>
<p>We thank Mr. Pramdan for running the experiments. We are grateful to Emirates Foundation for their fund support.</p></sec></ack>
<refgrp><bibl id="B1"><title><p>Updated national birth prevalence estimates for selected birth defects in the United States, 2004&#8211;2006 birth defects</p></title><aug><au><snm>Parker</snm><fnm>SE</fnm></au><au><snm>Mai</snm><fnm>CT</fnm></au><au><snm>Canfield</snm><fnm>MA</fnm></au><au><snm>Rickard</snm><fnm>R</fnm></au><au><snm>Wang</snm><fnm>Y</fnm></au><au><snm>Meyer</snm><fnm>RE</fnm></au><au><snm>Anderson</snm><fnm>P</fnm></au><au><snm>Mason</snm><fnm>CA</fnm></au><au><snm>Collins</snm><fnm>JS</fnm></au><au><snm>Kirby</snm><fnm>RS</fnm></au><au><snm>Correa</snm><fnm>A</fnm></au></aug><source>Res A Clin Mol Teratol</source><pubdate>2010</pubdate><volume>88</volume><fpage>100</fpage><lpage>1016</lpage></bibl><bibl id="B2"><title><p>Energy expenditure in children with Down syndrome: Correcting metabolic rate for movement</p></title><aug><au><snm>Luke</snm><fnm>A</fnm></au><au><snm>Roizen</snm><fnm>NJ</fnm></au><au><snm>Sutton</snm><fnm>M</fnm></au><au><snm>Shoeller</snm><fnm>DA</fnm></au></aug><source>J Pediatr</source><pubdate>1994</pubdate><volume>125</volume><fpage>829</fpage><lpage>838</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0022-3476(06)80193-9</pubid><pubid idtype="pmpid" link="fulltext">7965444</pubid></pubidlist></xrefbib></bibl><bibl id="B3"><title><p>Down syndrome: Immunologic and Epidemiologic association-Enigmas remain</p></title><aug><au><snm>Doglus</snm><fnm>S</fnm></au></aug><source>J Pediatr</source><pubdate>2005</pubdate><volume>147</volume><fpage>724</fpage><lpage>725</lpage></bibl><bibl id="B4"><title><p>Thyroid function in adults with Down's syndrome</p></title><aug><au><snm>Murdoch</snm><fnm>JC</fnm></au><au><snm>Ratcliffe</snm><fnm>WA</fnm></au><au><snm>McLarty</snm><fnm>DG</fnm></au><au><snm>Rodger</snm><fnm>JC</fnm></au><au><snm>Ratcliffe</snm><fnm>JG</fnm></au></aug><source>J Clin Endocrinol Metab</source><pubdate>1977</pubdate><volume>44</volume><fpage>453</fpage><lpage>458</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1210/jcem-44-3-453</pubid><pubid idtype="pmpid" link="fulltext">138688</pubid></pubidlist></xrefbib></bibl><bibl id="B5"><title><p>T-lymphocytes apoptosis and mitochondrial membrane potential in Down's syndrome</p></title><aug><au><snm>Abu Faddan</snm><fnm>N</fnm></au><au><snm>Sayed</snm><fnm>D</fnm></au><au><snm>Ghaleb</snm><fnm>F</fnm></au></aug><source>Fetal and Pediatric Pathology</source><pubdate>2011</pubdate><volume>30</volume><fpage>45</fpage><lpage>52</lpage><xrefbib><pubidlist><pubid idtype="doi">10.3109/15513815.2010.505626</pubid><pubid idtype="pmpid" link="fulltext">21204666</pubid></pubidlist></xrefbib></bibl><bibl id="B6"><title><p>Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F0 during ATP synthesis</p></title><aug><au><snm>Baracca</snm><fnm>A</fnm></au><au><snm>Sgarbi</snm><fnm>G</fnm></au><au><snm>Solaini</snm><fnm>G</fnm></au><au><snm>Lenaz</snm><fnm>G</fnm></au></aug><source>Biochim Biophys Acta</source><pubdate>2003</pubdate><volume>1606</volume><fpage>137</fpage><lpage>146</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0005-2728(03)00110-5</pubid><pubid idtype="pmpid" link="fulltext">14507434</pubid></pubidlist></xrefbib></bibl><bibl id="B7"><title><p>Reactive oxygen species and mitochondrial diseases</p></title><aug><au><snm>Kirkinezos</snm><fnm>IG</fnm></au><au><snm>Moraes</snm><fnm>CT</fnm></au></aug><source>Seminars in Cell &amp; Developmental Biology</source><pubdate>2001</pubdate><volume>12</volume><fpage>449</fpage><lpage>457</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1006/scdb.2001.0282</pubid><pubid idtype="pmpid" link="fulltext">23167399</pubid></pubidlist></xrefbib></bibl><bibl id="B8"><title><p>Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry</p></title><aug><au><snm>Sureda</snm><fnm>FX</fnm></au><au><snm>Escubedo</snm><fnm>E</fnm></au><au><snm>Gabriel</snm><fnm>C</fnm></au><au><snm>Comas</snm><fnm>J</fnm></au><au><snm>Camarasa</snm><fnm>J</fnm></au><au><snm>Camins</snm><fnm>A</fnm></au></aug><source>Cytometry</source><pubdate>1997</pubdate><volume>28</volume><fpage>74</fpage><lpage>80</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/(SICI)1097-0320(19970501)28:1&lt;74::AID-CYTO9&gt;3.0.CO;2-H</pubid><pubid idtype="pmpid" link="fulltext">9136758</pubid></pubidlist></xrefbib></bibl><bibl id="B9"><title><p>Mitochondrial enzyme deficiencies in Down's syndrome</p></title><aug><au><snm>Prince</snm><fnm>J</fnm></au><au><snm>Jia</snm><fnm>S</fnm></au><au><snm>B&#229;ve</snm><fnm>U</fnm></au><au><snm>Anner&#233;n</snm><fnm>G</fnm></au><au><snm>Oreland</snm><fnm>L</fnm></au></aug><source>J Neural Transm Park Dis Dement Sect</source><pubdate>1994</pubdate><volume>8</volume><fpage>171</fpage><lpage>181</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF02260938</pubid><pubid idtype="pmpid">7748461</pubid></pubidlist></xrefbib></bibl><bibl id="B10"><title><p>Platelet abnormalities in Down's syndrome</p></title><aug><au><snm>More</snm><fnm>R</fnm></au><au><snm>Amir</snm><fnm>N</fnm></au><au><snm>Meyer</snm><fnm>S</fnm></au><au><snm>Kopolovic</snm><fnm>J</fnm></au><au><snm>Yarom</snm><fnm>R</fnm></au></aug><source>Clin Genet</source><pubdate>1982</pubdate><volume>22</volume><fpage>128</fpage><lpage>136</lpage><xrefbib><pubid idtype="pmpid">6217927</pubid></xrefbib></bibl><bibl id="B11"><title><p>The phosphorescence oxygen analyzer as a screening tool for disorders with impaired lymphocyte bioenergetics</p></title><aug><au><snm>Al-Jasmi</snm><fnm>F</fnm></au><au><snm>Penefsky</snm><fnm>HS</fnm></au><au><snm>Souid</snm><fnm>A-K</fnm></au></aug><source>Mol Genet Metab</source><pubdate>2011</pubdate><volume>104</volume><fpage>529</fpage><lpage>536</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.ymgme.2011.09.023</pubid><pubid idtype="pmpid" link="fulltext">21996136</pubid></pubidlist></xrefbib></bibl><bibl id="B12"><title><p>Oxygen measurements via phosphorescence</p></title><aug><au><snm>Shaban</snm><fnm>S</fnm></au><au><snm>Marzouqi</snm><fnm>F</fnm></au><au><snm>Al Mansouri</snm><fnm>A</fnm></au><au><snm>Penefsky</snm><fnm>HS</fnm></au><au><snm>Souid</snm><fnm>AK</fnm></au></aug><source>Comput Methods Programs Biomed</source><pubdate>2010</pubdate><volume>100</volume><fpage>265</fpage><lpage>268</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.cmpb.2010.04.009</pubid><pubid idtype="pmpid" link="fulltext">20478639</pubid></pubidlist></xrefbib></bibl><bibl id="B13"><title><p>Immediate effects of anticancer drugs on mitochondrial oxygen consumption</p></title><aug><au><snm>Souid</snm><fnm>AK</fnm></au><au><snm>Tacka</snm><fnm>KA</fnm></au><au><snm>Galvan</snm><fnm>KA</fnm></au><au><snm>Penefsky</snm><fnm>HS</fnm></au></aug><source>Biochem Pharmacol</source><pubdate>2003</pubdate><volume>66</volume><fpage>977</fpage><lpage>987</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0006-2952(03)00418-0</pubid><pubid idtype="pmpid" link="fulltext">12963484</pubid></pubidlist></xrefbib></bibl><bibl id="B14"><title><p>Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: A phosphor with general application for measuring oxygen concentration in biological systems</p></title><aug><au><snm>Lo</snm><fnm>L-W</fnm></au><au><snm>Koch</snm><fnm>CJ</fnm></au><au><snm>Wilson</snm><fnm>DF</fnm></au></aug><source>Anal Biochem</source><pubdate>1996</pubdate><volume>236</volume><fpage>153</fpage><lpage>160</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1006/abio.1996.0144</pubid><pubid idtype="pmpid" link="fulltext">8619481</pubid></pubidlist></xrefbib></bibl><bibl id="B15"><title><p>Protein metabolism in human obesity: relationship with glucose and lipid metabolism and with visceral adipose tissue</p></title><aug><au><snm>Solini</snm><fnm>A</fnm></au><au><snm>Bonora</snm><fnm>E</fnm></au><au><snm>Bonadonna</snm><fnm>R</fnm></au><au><snm>Castellino</snm><fnm>P</fnm></au><au><snm>DeFronzo</snm><fnm>RA</fnm></au></aug><source>J Clin Endocrinol Metab</source><pubdate>1997</pubdate><volume>82</volume><fpage>2552</fpage><lpage>2558</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1210/jc.82.8.2552</pubid><pubid idtype="pmpid" link="fulltext">9253333</pubid></pubidlist></xrefbib></bibl><bibl id="B16"><title><p>Protein metabolism in obesity: effects of body fat distribution and hyperinsulinemia on leucine turnover</p></title><aug><au><snm>Jensen</snm><fnm>MD</fnm></au><au><snm>Haymond</snm><fnm>MW</fnm></au></aug><source>Am J Clin Nutr</source><pubdate>1991</pubdate><volume>5</volume><fpage>172</fpage><lpage>176</lpage></bibl><bibl id="B17"><title><p>Cerebral oxygen consumption in Down's syndrome</p></title><aug><au><snm>Lassen</snm><fnm>NA</fnm></au><au><snm>Christensen</snm><fnm>S</fnm></au><au><snm>Hoedt-Rasmussen</snm><fnm>K</fnm></au><au><snm>Stewart</snm><fnm>BM</fnm></au></aug><source>Arch Neurol</source><pubdate>1966</pubdate><volume>15</volume><fpage>595</fpage><lpage>602</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1001/archneur.1966.00470180035004</pubid><pubid idtype="pmpid" link="fulltext">4224459</pubid></pubidlist></xrefbib></bibl><bibl id="B18"><title><p>The relation of oxygen consumption to cerebral function activity</p></title><aug><au><snm>Garfunkel</snm><fnm>JM</fnm></au><au><snm>Baird</snm><fnm>HW</fnm></au><au><snm>Ziegler</snm><fnm>J</fnm></au></aug><source>J Pediatr</source><pubdate>1954</pubdate><volume>44</volume><fpage>64</fpage><lpage>72</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0022-3476(54)80093-X</pubid><pubid idtype="pmpid">13131199</pubid></pubidlist></xrefbib></bibl><bibl id="B19"><title><p>Oxidative stress and mitochondrial dysfunction in Down syndrome</p></title><aug><au><snm>Pagano</snm><fnm>G</fnm></au><au><snm>Castello</snm><fnm>G</fnm></au></aug><source>Adv Exp Med Bio</source><pubdate>2012</pubdate><volume>724</volume><fpage>291</fpage><lpage>299</lpage><xrefbib><pubid idtype="doi">10.1007/978-1-4614-0653-2_22</pubid></xrefbib></bibl><bibl id="B20"><title><p>Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signaling pathway</p></title><aug><au><snm>Valenti</snm><fnm>D</fnm></au><au><snm>Manente</snm><fnm>GA</fnm></au><au><snm>Moro</snm><fnm>L</fnm></au><au><snm>Marra</snm><fnm>E</fnm></au><au><snm>Vacca</snm><fnm>RA</fnm></au></aug><source>Biochem J</source><pubdate>2011</pubdate><volume>435</volume><fpage>679</fpage><lpage>688</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1042/BJ20101908</pubid><pubid idtype="pmpid" link="fulltext">21338338</pubid></pubidlist></xrefbib></bibl><bibl id="B21"><title><p>Impairment of methyl cycle affects mitochondrial methyl availability and glutathione level in Down's syndrome</p></title><aug><au><snm>Infantino</snm><fnm>V</fnm></au><au><snm>Castegna</snm><fnm>A</fnm></au><au><snm>Iacobazzi</snm><fnm>F</fnm></au><au><snm>Spera</snm><fnm>I</fnm></au><au><snm>Scala</snm><fnm>I</fnm></au><au><snm>Andria</snm><fnm>G</fnm></au><au><snm>Iacobazzi</snm><fnm>V</fnm></au></aug><source>Mol Genet Metab</source><pubdate>2011</pubdate><volume>102</volume><fpage>378</fpage><lpage>382</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.ymgme.2010.11.166</pubid><pubid idtype="pmpid" link="fulltext">21195648</pubid></pubidlist></xrefbib></bibl><bibl id="B22"><title><p>Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anemia and Werner Syndrome</p></title><aug><au><snm>Pallard&#243;</snm><fnm>FV</fnm></au><au><snm>Lloret</snm><fnm>A</fnm></au><au><snm>Lebel</snm><fnm>M</fnm></au><au><snm>d&apos;Ischia</snm><fnm>M</fnm></au><au><snm>Cogger</snm><fnm>VC</fnm></au><au><snm>Le Couteur</snm><fnm>DG</fnm></au><au><snm>Gadaleta</snm><fnm>MN</fnm></au><au><snm>Castello</snm><fnm>G</fnm></au><au><snm>Pagano</snm><fnm>G</fnm></au></aug><source>Biogerontology</source><pubdate>2010</pubdate><volume>11</volume><fpage>401</fpage><lpage>419</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s10522-010-9269-4</pubid><pubid idtype="pmpid" link="fulltext">20237955</pubid></pubidlist></xrefbib></bibl><bibl id="B23"><title><p>Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy</p></title><aug><au><snm>Valenti</snm><fnm>D</fnm></au><au><snm>Tullo</snm><fnm>A</fnm></au><au><snm>Caratozzolo</snm><fnm>MF</fnm></au><au><snm>Merafina</snm><fnm>RS</fnm></au><au><snm>Scartezzini</snm><fnm>P</fnm></au><au><snm>Marra</snm><fnm>E</fnm></au><au><snm>Vacca</snm><fnm>RA</fnm></au></aug><source>Biochem J</source><pubdate>2010</pubdate><volume>431</volume><fpage>299</fpage><lpage>310</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1042/BJ20100581</pubid><pubid idtype="pmpid" link="fulltext">20698827</pubid></pubidlist></xrefbib></bibl></refgrp><sec><st><p>Pre-publication history</p></st><p>The pre-publication history for this paper can be accessed here:</p><p><url>http://www.biomedcentral.com/1471-2431/12/193/prepub</url></p></sec></bm></art>